Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery

Sponsor
Sun Yat-sen University (Other)
Overall Status
Completed
CT.gov ID
NCT02681679
Collaborator
Ministry of Health, China (Other)
60
1
2
14
4.3

Study Details

Study Description

Brief Summary

Since a new generation of femtosecond lasers became available for cataract surgery in 2009, the use of this image-guided system has provided several benefits, including a reduction in phacoemulsification energy by prefragmentation of the crystalline lens, and the potential advantages of more precise corneal incisions and capsulotomy formation. However, as with any new surgical technique, femtosecond laser cataract surgery also has potential complications. Intraoperative miosis is one of the most common intraoperative complications of femtosecond laser-assisted cataract surgery, with a reported prevalence ranging from 9.5 to 32.0%.8 Significant pupillary constriction necessitates the removal of the anterior capsule flap, fragmented nucleus and remaining cortex, which is potentially associated with a higher rate of surgery-related complications.

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.1% bromfenac ophthalmic solution
  • Procedure: femtosecond laser cataract surgery
N/A

Detailed Description

Since a new generation of femtosecond lasers became available for cataract surgery in 2009, the use of this image-guided system has provided several benefits, including a reduction in phacoemulsification energy by prefragmentation of the crystalline lens, and the potential advantages of more precise corneal incisions and capsulotomy formation. However, as with any new surgical technique, femtosecond laser cataract surgery also has potential complications. Intraoperative miosis is one of the most common intraoperative complications of femtosecond laser-assisted cataract surgery, with a reported prevalence ranging from 9.5 to 32.0%. Significant pupillary constriction necessitates the removal of the anterior capsule flap, fragmented nucleus and remaining cortex, which is potentially associated with a higher rate of surgery-related complications.

Intraoperative miosis may be due to the intraocular effects that occur after femtosecond laser pretreatment. The intraocular tissues may be exposed to laser emissions, and lens proteins can be released into the anterior chamber. Together, these events trigger the release of unwanted cytokines. In a previous study, intraocular prostaglandin concentrations were found to be increased immediately after femtosecond laser pretreatment. Prostaglandins, especially prostaglandin E2 (PGE2), are known to play a role in inflammation-induced miosis.

Preoperative topical treatment with NSAIDs inhibits the release of prostaglandins in response to surgically-induced miosis by suppressing cyclooxygenase, the enzyme that transforms arachidonic acid into prostaglandin precursors. The effectiveness of ophthalmic NSAIDs in preventing miosis has been well documented in conventional phacoemulsification cataract surgery. However, whether this effect is also applicable to femtosecond laser-assisted cataract surgery is unknown. Yeoh has suggested the addition of NSAID eye drops to the dilation regimen during femtosecond laser cataract surgery, but no randomized study has been conducted to support this theory. Given the increasing popularity of femtosecond laser-assisted cataract surgery, the investigators sought to study whether topical NSAIDs might be beneficial in pupil maintenance and PGE2 inhibition during the procedure.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Topical 0.1% Bromfenac Sodium for Intraoperative Pupil Dilation Maintenance and Prostaglandin E2 Inhibition in Femtosecond Laser-assisted Cataract Surgery
Study Start Date :
Oct 1, 2014
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: 0.1% bromfenac ophthalmic solution

Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.

Drug: 0.1% bromfenac ophthalmic solution

Procedure: femtosecond laser cataract surgery

Placebo Comparator: control physiological normal saline

Patients received control physiological normal saline twice a day for 3 days before surgery.

Procedure: femtosecond laser cataract surgery

Outcome Measures

Primary Outcome Measures

  1. Pupil area measured using ImageJ software A [surgery]

  2. PGE2 levels measured with an enzyme-linked immunoassay [2 days after surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • if they were 50 years of age or older and were scheduled to undergo femtosecond laser cataract surgery
Exclusion Criteria:
  • a previous history of intraocular surgery;

  • recent trauma;

  • uveitis;

  • systemic disease, such as diabetes mellitus; hypertension;

  • the use of systemic or topical NSAIDs within 1 week of enrollment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong China 510060

Sponsors and Collaborators

  • Sun Yat-sen University
  • Ministry of Health, China

Investigators

  • Principal Investigator: Haotian Lin, M.D. Ph.D, Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Haotian Lin, Principle investigator, Childhood Cataract Program of the Chinese Ministry of Health(CCPMOH), Zhongshan Ophthalmic Center, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT02681679
Other Study ID Numbers:
  • CCPMOH2016-China-1
First Posted:
Feb 12, 2016
Last Update Posted:
Feb 12, 2016
Last Verified:
Feb 1, 2016
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 12, 2016